adenosine-kinase and Coronary-Thrombosis

adenosine-kinase has been researched along with Coronary-Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for adenosine-kinase and Coronary-Thrombosis

ArticleYear
Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
    The Journal of clinical investigation, 1994, Volume: 94, Issue:4

    Inhibition of platelet aggregation by acadesine was evaluated both in vitro and ex vivo in human whole blood using impedance aggregometry, as well as in vivo in a canine model of platelet-dependent cyclic coronary flow reductions. In vitro, incubation of acadesine in whole blood inhibited ADP-induced platelet aggregation by 50% at 240 +/- 60 microM. Inhibition of platelet aggregation was time dependent and was prevented by the adenosine kinase inhibitor, 5'-deoxy 5-iodotubercidin, which blocked conversion of acadesine to its 5'-monophosphate, ZMP, and by adenosine deaminase. Acadesine elevated platelet cAMP in whole blood, which was also prevented by adenosine deaminase. In contrast, acadesine had no effect on ADP-induced platelet aggregation or platelet cAMP levels in platelet-rich plasma, but inhibition of aggregation was restored when isolated erythrocytes were incubated with acadesine before reconstitution with platelet-rich plasma. Acadesine (100 mg/kg i.v.) administered to human subjects also inhibited platelet aggregation ex vivo in whole blood. In the canine Folts model of platelet thrombosis, acadesine (0.5 mg/kg per min, i.v.) abolished coronary flow reductions, and this activity was prevented by pretreatment with the adenosine receptor antagonist, 8-sulphophenyltheophylline. These results demonstrate that acadesine exhibits antiplatelet activity in vitro, ex vivo, and in vivo through an adenosine-dependent mechanism. Moreover, the in vitro studies indicate that inhibition of platelet aggregation requires the presence of erythrocytes and metabolism of acadesine to acadesine monophosphate (ZMP).

    Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Aminoimidazole Carboxamide; Animals; Aspirin; Blood Physiological Phenomena; Coronary Thrombosis; Coronary Vessels; Dipyridamole; Disease Models, Animal; Dogs; Erythrocytes; Humans; Male; Plasma; Platelet Aggregation; Purinergic P1 Receptor Antagonists; Regional Blood Flow; Ribonucleosides; Theophylline; Tubercidin

1994